Dr Michaela Kirschner

Postdoctoral Research Fellow
Medicine, Concord Clinical School
Asbestos Diseases Research Institute

Telephone +61 2 9767 9800
Fax +61 2 9767 9860

Website Related website
Curriculum vitae Curriculum vitae

Map

Research interests

Dr Kirschner is working as a postdoctoral research fellow at the Asbestos Diseases Research Institute (ADRI). The ADRI undertakes translational research with the aim to improve diagnosis and treatment of malignant pleural mesothelioma.

The main focus of Dr Kirschner's work is on the identification of novel diagnostic and/or prognostic biomarkers for malignant pleural mesothelioma, and I am mainly working on two microRNA-based projects:

1) Cell-free microRNAs in the circulation as (early) diagnostic markers for malignant pleural mesothelioma

2) Tumour microRNAs as markers predicting patients benefiting from radical surgery.

In addition Dr Kirschner is also involved in projects investigating the functional role both microRNAs and long non-coding RNAs play in the development/progression of malignant pleural mesothelioma.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Linton, A., Cheng, Y., Griggs, K., Kirschner, M., Gattani, S., Srikaran, S., Kao, S., McCaughan, B., Klebe, S., van Zandwijk, N., Reid, G. (2014). An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. British Journal of Cancer, 110(2), 510-519. [More Information]
  • Kirschner, M., van Zandwijk, N., Reid, G. (2013). Cell-free microRNAs: potential biomarkers in need of standardized reporting. Frontiers in Genetics, 4, 1-5. [More Information]
  • Wright, C., Kirschner, M., van Zandwijk, N., Reid, G. (2013). Does miR-1 play a role in malignant pleural mesothelioma development and progression? Chest, 144(6), 1971. [More Information]
  • Wright, C., Kirschner, M., Cheng, Y., O’Byrne, K., Gray, S., Schelch, K., Hoda, M., Klebe, S., McCaughan, B., van Zandwijk, N., Reid, G. (2013). Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM). PLoS One, 8(8), 1-12. [More Information]
  • Reid, G., Pel, M., Kirschner, M., Cheng, Y., Amaro-Mugridge, N., Madrid-Weiss, J., Williams, M., Wright, C., Edelman, J., Vallely, M., van Zandwijk, N., et al (2013). Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Annals of Oncology, 24(12), 3128-3135. [More Information]
  • Kirschner, M., Edelman, J., Kao, S., Vallely, M., van Zandwijk, N., Reid, G. (2013). The Impact of Hemolysis on Cell-Free microRNA Biomarkers. Frontiers in Genetics, 4, 1-13. [More Information]
  • Cheng, Y., Kirschner, M., Cheng, N., Gattani, S., Klebe, S., Edelman, J., Vallely, M., McCaughan, B., Jin, H., van Zandwijk, N., Reid, G. (2013). ZIC1 Is Silenced and Has Tumor Suppressor Function in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 8(10), 1317-1328. [More Information]
  • Kirschner, M., Cheng, V., Badrian, B., Kao, S., Creaney, J., Edelman, J., Armstrong, N., Vallely, M., Musk, A., Robinson, B., McCaughan, B., van Zandwijk, N., Reid, G., et al (2012). Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 7(7), 1184-1191. [More Information]
  • Reid, G., Kirschner, M., van Zandwijk, N. (2011). Circulating microRNAs: Association with disease and potential use as biomarkers. Critical Reviews in Oncology / Hematology, 80(2), 193-208. [More Information]
  • Kirschner, M., Kao, S., Edelman, J., Armstrong, N., Vallely, M., van Zandwijk, N., Reid, G. (2011). Haemolysis during Sample Preparation Alters microRNA Content of Plasma. PLoS One, 6(9), 1-9. [More Information]
  • Kirschner, M., Leupold, J., Schmidt, K., Post, S., Manegold, C., Allgayer, H. (2007). Zoledronic acid reduces invasion of different lung cancer cell lines. European Journal of Cancer Supplements, 5(4), 367-367.

Conferences

  • Kirschner, M., Leupold, J., Schmidt, K., Post, S., Manegold, C., Allgayer, H. (2008). Zoledronic acid treatment leads to reduced invasion and tumor growth of lung cancer cells. International Thoracic Oncology Congress Dresden (ITOCD): Advances through Molecular Biology in Thoracic Cancer, Germany.

2014

  • Linton, A., Cheng, Y., Griggs, K., Kirschner, M., Gattani, S., Srikaran, S., Kao, S., McCaughan, B., Klebe, S., van Zandwijk, N., Reid, G. (2014). An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. British Journal of Cancer, 110(2), 510-519. [More Information]

2013

  • Kirschner, M., van Zandwijk, N., Reid, G. (2013). Cell-free microRNAs: potential biomarkers in need of standardized reporting. Frontiers in Genetics, 4, 1-5. [More Information]
  • Wright, C., Kirschner, M., van Zandwijk, N., Reid, G. (2013). Does miR-1 play a role in malignant pleural mesothelioma development and progression? Chest, 144(6), 1971. [More Information]
  • Wright, C., Kirschner, M., Cheng, Y., O’Byrne, K., Gray, S., Schelch, K., Hoda, M., Klebe, S., McCaughan, B., van Zandwijk, N., Reid, G. (2013). Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM). PLoS One, 8(8), 1-12. [More Information]
  • Reid, G., Pel, M., Kirschner, M., Cheng, Y., Amaro-Mugridge, N., Madrid-Weiss, J., Williams, M., Wright, C., Edelman, J., Vallely, M., van Zandwijk, N., et al (2013). Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Annals of Oncology, 24(12), 3128-3135. [More Information]
  • Kirschner, M., Edelman, J., Kao, S., Vallely, M., van Zandwijk, N., Reid, G. (2013). The Impact of Hemolysis on Cell-Free microRNA Biomarkers. Frontiers in Genetics, 4, 1-13. [More Information]
  • Cheng, Y., Kirschner, M., Cheng, N., Gattani, S., Klebe, S., Edelman, J., Vallely, M., McCaughan, B., Jin, H., van Zandwijk, N., Reid, G. (2013). ZIC1 Is Silenced and Has Tumor Suppressor Function in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 8(10), 1317-1328. [More Information]

2012

  • Kirschner, M., Cheng, V., Badrian, B., Kao, S., Creaney, J., Edelman, J., Armstrong, N., Vallely, M., Musk, A., Robinson, B., McCaughan, B., van Zandwijk, N., Reid, G., et al (2012). Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 7(7), 1184-1191. [More Information]

2011

  • Reid, G., Kirschner, M., van Zandwijk, N. (2011). Circulating microRNAs: Association with disease and potential use as biomarkers. Critical Reviews in Oncology / Hematology, 80(2), 193-208. [More Information]
  • Kirschner, M., Kao, S., Edelman, J., Armstrong, N., Vallely, M., van Zandwijk, N., Reid, G. (2011). Haemolysis during Sample Preparation Alters microRNA Content of Plasma. PLoS One, 6(9), 1-9. [More Information]

2008

  • Kirschner, M., Leupold, J., Schmidt, K., Post, S., Manegold, C., Allgayer, H. (2008). Zoledronic acid treatment leads to reduced invasion and tumor growth of lung cancer cells. International Thoracic Oncology Congress Dresden (ITOCD): Advances through Molecular Biology in Thoracic Cancer, Germany.

2007

  • Kirschner, M., Leupold, J., Schmidt, K., Post, S., Manegold, C., Allgayer, H. (2007). Zoledronic acid reduces invasion of different lung cancer cell lines. European Journal of Cancer Supplements, 5(4), 367-367.

To update your profile click here. For support on your academic profile contact .